专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09096559B2 4-carboxybenzylamino derivatives as histone deacetylase inhibitors 有权
标题翻译： 4-羧基苄基氨基衍生物作为组蛋白脱乙酰酶抑制剂
公开(公告)号：US09096559B2
公开(公告)日：2015-08-04
申请号：US13751789
申请日：2013-01-28
申请人： Paul Harrington , Richard W. Heidebrecht, Jr. , Solomon Kattar , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , Matthew G. Stanton , Paul Tempest , Kevin J. Wilson , David J. Witter
发明人： Paul Harrington , Richard W. Heidebrecht, Jr. , Solomon Kattar , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , Matthew G. Stanton , Paul Tempest , Kevin J. Wilson , David J. Witter
IPC分类号： C07D333/10 , C07C235/76 , C07C235/84 , C07D295/155 , C07C237/40 , C07C237/42 , C07C271/22 , C07C271/38 , C07C271/54 , C07D207/08 , C07D207/14 , C07D207/16 , C07D209/44 , C07D209/48 , C07D211/14 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/56 , C07D213/74 , C07D217/04 , C07D231/12 , C07D233/64 , C07D241/12 , C07D263/20 , C07D277/28 , C07D295/125 , C07D307/22 , C07D333/20 , C07D401/04 , C07D409/12 , C07D413/12 , C07D213/55
CPC分类号： C07D295/155 , C07C237/40 , C07C237/42 , C07C271/22 , C07C271/38 , C07C271/54 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/08 , C07D207/14 , C07D207/16 , C07D209/44 , C07D209/48 , C07D211/14 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/55 , C07D213/56 , C07D213/74 , C07D217/04 , C07D231/12 , C07D233/64 , C07D241/12 , C07D263/20 , C07D277/28 , C07D295/125 , C07D307/22 , C07D333/10 , C07D333/20 , C07D401/04 , C07D409/12 , C07D413/12
摘要： The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.
摘要翻译：本发明涉及一类新的4-羧基苄基氨基衍生物。 4-羧基苄基氨基化合物可用于治疗癌症。 4-羧基苄基氨基化合物也可以抑制组蛋白脱乙酰酶，适用于选择性诱导末端分化，阻止肿瘤细胞的细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫性，过敏性和炎性疾病，以及预防和/或治疗中枢神经系统（CNS）的疾病，例如神经退行性疾病本发明进一步提供包含4-羧基苄基氨基衍生物和这些药物组合物的安全投药方案的药物组合物，其易于遵循，并且其在体内导致治疗有效量的4-羧基苄基氨基衍生物。

2. 发明申请

US20130137690A1 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS 审中-公开
标题翻译： 4-羧基苯甲酰胺衍生物作为脱乙酰壳多糖酶抑制剂
公开(公告)号：US20130137690A1
公开(公告)日：2013-05-30
申请号：US13751789
申请日：2013-01-28
申请人： Paul Harrington , Richard W. Heidebrecht, JR. , Solomon Kattar , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , Matthew G. Stanton , Paul Tempest , Kevin J. Wilson , David J. Witter
发明人： Paul Harrington , Richard W. Heidebrecht, JR. , Solomon Kattar , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , Matthew G. Stanton , Paul Tempest , Kevin J. Wilson , David J. Witter
IPC分类号： C07D295/155 , A61K31/5377 , C07D213/55 , C07D403/02 , C07D413/14 , A61K31/496 , C07D409/14
CPC分类号： C07D295/155 , C07C237/40 , C07C237/42 , C07C271/22 , C07C271/38 , C07C271/54 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/08 , C07D207/14 , C07D207/16 , C07D209/44 , C07D209/48 , C07D211/14 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/55 , C07D213/56 , C07D213/74 , C07D217/04 , C07D231/12 , C07D233/64 , C07D241/12 , C07D263/20 , C07D277/28 , C07D295/125 , C07D307/22 , C07D333/10 , C07D333/20 , C07D401/04 , C07D409/12 , C07D413/12
摘要： The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.
摘要翻译：本发明涉及一类新的4-羧基苄基氨基衍生物。 4-羧基苄基氨基化合物可用于治疗癌症。 4-羧基苄基氨基化合物也可以抑制组蛋白脱乙酰酶，适用于选择性诱导末端分化，阻止肿瘤细胞的细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫性，过敏性和炎性疾病，以及预防和/或治疗中枢神经系统（CNS）的疾病，例如神经退行性疾病本发明进一步提供包含4-羧基苄基氨基衍生物和这些药物组合物的安全投药方案的药物组合物，其易于遵循，并且其在体内导致治疗有效量的4-羧基苄基氨基衍生物。

3. 发明申请

US20100324046A1 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS 有权
标题翻译： 4-羧基苯甲酰胺衍生物作为脱乙酰壳多糖酶抑制剂
公开(公告)号：US20100324046A1
公开(公告)日：2010-12-23
申请号：US12666384
申请日：2008-06-24
申请人： Paul Harrington , Richard W. Heidebrecht, JR. , Solomon Kattar , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , Paul Tempest , Kevin J. Wilson , David J. Witter
发明人： Paul Harrington , Richard W. Heidebrecht, JR. , Solomon Kattar , Thomas A. Miller , Karin M. Otte , Phieng Siliphaivanh , Paul Tempest , Kevin J. Wilson , David J. Witter
IPC分类号： A61K31/5375 , C07D213/56 , C07D401/12 , C07D409/12 , C07C271/22 , C07C237/40 , C07D333/24 , C07D213/74 , C07D231/12 , C07D277/30 , C07D233/61 , C07D207/09 , C07D241/04 , C07D265/30 , C07D211/34 , C07D217/04 , C07D209/44 , C07D207/14 , C07D307/22 , C07D263/22 , C07D249/04 , A61K31/4406 , A61K31/444 , A61K31/4436 , A61K31/27 , A61K31/167 , A61K31/381 , A61K31/4025 , A61K31/4409 , A61K31/415 , A61K31/426 , A61K31/4174 , A61K31/40 , A61K31/4965 , A61K31/4453 , A61K31/472 , A61K31/4035 , A61K31/341 , A61K31/4439 , A61K31/421 , A61K31/4192 , A61P35/00
CPC分类号： C07D295/155 , C07C237/40 , C07C237/42 , C07C271/22 , C07C271/38 , C07C271/54 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/08 , C07D207/14 , C07D207/16 , C07D209/44 , C07D209/48 , C07D211/14 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/55 , C07D213/56 , C07D213/74 , C07D217/04 , C07D231/12 , C07D233/64 , C07D241/12 , C07D263/20 , C07D277/28 , C07D295/125 , C07D307/22 , C07D333/10 , C07D333/20 , C07D401/04 , C07D409/12 , C07D413/12
摘要： The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.
摘要翻译：本发明涉及一类新的4-羧基苄基氨基衍生物。 4-羧基苄基氨基化合物可用于治疗癌症。 4-羧基苄基氨基化合物也可以抑制组蛋白脱乙酰酶，适用于选择性诱导末端分化，阻止肿瘤细胞的细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫性，过敏性和炎性疾病，以及预防和/或治疗中枢神经系统疾病（CNS），例如神经退行性疾病本发明进一步提供包含4-羧基苄基氨基衍生物和这些药物组合物的安全投药方案的药物组合物，其易于遵循，并且其在体内导致治疗有效量的4-羧基苄基氨基衍生物。

4. 发明授权

US08389553B2 4-carboxybenzylamino derivatives as histone deacetylase inhibitors 有权
公开(公告)号：US08389553B2
公开(公告)日：2013-03-05
申请号：US12666384
申请日：2008-06-24
申请人： Paul Harrington , Solomon Kattar , Thomas A. Miller , Matthew G. Stanton , Paul Tempest , David J. Witter
发明人： Paul Harrington , Solomon Kattar , Thomas A. Miller , Matthew G. Stanton , Paul Tempest , David J. Witter
IPC分类号： A01N43/40 , A01N47/10 , A61K31/44 , A61K31/27 , C07D213/55 , C07D213/00 , C07D211/30 , C07D211/32 , C07D217/00
CPC分类号： C07D295/155 , C07C237/40 , C07C237/42 , C07C271/22 , C07C271/38 , C07C271/54 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/08 , C07D207/14 , C07D207/16 , C07D209/44 , C07D209/48 , C07D211/14 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/55 , C07D213/56 , C07D213/74 , C07D217/04 , C07D231/12 , C07D233/64 , C07D241/12 , C07D263/20 , C07D277/28 , C07D295/125 , C07D307/22 , C07D333/10 , C07D333/20 , C07D401/04 , C07D409/12 , C07D413/12
摘要： The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.

5. 发明授权

US08158825B2 Modified malonate derivatives 有权
标题翻译：改性丙二酸酯衍生物
公开(公告)号：US08158825B2
公开(公告)日：2012-04-17
申请号：US11922740
申请日：2006-06-21
申请人： Jonathan Grimm , Paul Harrington , Richard Heidebrecht, Jr. , Thomas Miller , Karin Otte , Phieng Siliphaivanh , David Sloman , Matthew Stanton , Kevin Wilson , David Witter , Solomon Kattar , Paul Tempest
发明人： Jonathan Grimm , Paul Harrington , Richard Heidebrecht, Jr. , Thomas Miller , Karin Otte , Phieng Siliphaivanh , David Sloman , Matthew Stanton , Kevin Wilson , David Witter , Solomon Kattar , Paul Tempest
IPC分类号： C07C233/02 , C07C255/60 , C07C311/46 , C07C311/08 , C07C235/84 , A61K31/519 , A61K31/44 , C07D265/30 , C07D495/04 , C07D215/06 , C07D211/06 , C07D213/82
CPC分类号： C07C235/78 , C07C233/75 , C07C233/80 , C07C235/42 , C07C235/56 , C07C235/74 , C07C235/84 , C07C255/60 , C07C311/08 , C07C311/16 , C07C311/46 , C07C2602/08 , C07D207/06 , C07D207/327 , C07D209/14 , C07D209/20 , C07D211/06 , C07D213/40 , C07D213/56 , C07D213/82 , C07D215/06 , C07D215/12 , C07D215/40 , C07D231/40 , C07D249/08 , C07D261/14 , C07D265/30 , C07D277/28 , C07D277/46 , C07D277/56 , C07D295/135 , C07D295/155 , C07D295/185 , C07D307/68 , C07D319/16 , C07D319/18 , C07D333/20 , C07D333/38 , C07D333/70 , C07D413/14 , C07D495/04
摘要： The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo.
摘要翻译：本发明涉及一类新型改性丙二酸衍生物。修饰的丙二酸酯化合物可用于治疗癌症。修饰的丙二酸酯化合物还可以抑制组蛋白脱乙酰酶，并且适用于选择性诱导末端分化，并阻止肿瘤细胞的细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫性，过敏性和炎性疾病，以及预防和/或治疗中枢神经系统（CNS）的疾病，例如神经退行性疾病本发明还提供包含改性丙二酸酯衍生物和这些药物组合物的安全给药方案的药物组合物，其易于遵循，并且其在体内导致治疗有效量的修饰的丙二酸酯衍生物。

6. 发明申请

US20100160327A1 Modified Malonate Derivatives 有权
标题翻译：改性丙二酸酯衍生物
公开(公告)号：US20100160327A1
公开(公告)日：2010-06-24
申请号：US11922740
申请日：2006-06-21
申请人： Jonathan Grimm , Paul Harrington , Richard Heidebrecht, JR. , Thomas Miller , Karin Otte , Phieng Siliphaivanh , David Sloman , Matthew Stanton , Kevin Wilson , David Witter , Solomon Kattar , Paul Tempest
发明人： Jonathan Grimm , Paul Harrington , Richard Heidebrecht, JR. , Thomas Miller , Karin Otte , Phieng Siliphaivanh , David Sloman , Matthew Stanton , Kevin Wilson , David Witter , Solomon Kattar , Paul Tempest
IPC分类号： A61K31/5375 , A61K31/519 , A61K31/47 , A61K31/4453 , A61K31/44 , A61K31/4409 , A61K31/426 , A61K31/42 , A61K31/4196 , A61K31/404 , A61K31/402 , A61K31/381 , A61K31/357 , A61K31/34 , A61K31/277 , A61K31/18 , A61K31/167 , C07D265/30 , C07D495/04 , C07D215/06 , C07D211/06 , C07D213/82 , C07D213/56 , C07D277/46 , C07D277/56 , C07D261/14 , C07D249/08 , C07D209/20 , C07D207/327 , C07D333/70 , C07D319/16 , C07D307/68 , C07C255/60 , C07C311/46 , C07C311/08 , C07C235/84 , A61P35/00
CPC分类号： C07C235/78 , C07C233/75 , C07C233/80 , C07C235/42 , C07C235/56 , C07C235/74 , C07C235/84 , C07C255/60 , C07C311/08 , C07C311/16 , C07C311/46 , C07C2602/08 , C07D207/06 , C07D207/327 , C07D209/14 , C07D209/20 , C07D211/06 , C07D213/40 , C07D213/56 , C07D213/82 , C07D215/06 , C07D215/12 , C07D215/40 , C07D231/40 , C07D249/08 , C07D261/14 , C07D265/30 , C07D277/28 , C07D277/46 , C07D277/56 , C07D295/135 , C07D295/155 , C07D295/185 , C07D307/68 , C07D319/16 , C07D319/18 , C07D333/20 , C07D333/38 , C07D333/70 , C07D413/14 , C07D495/04
摘要： The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the modified malonate derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the modified malonate derivatives in vivo.
摘要翻译：本发明涉及一类新型改性丙二酸衍生物。修饰的丙二酸酯化合物可用于治疗癌症。修饰的丙二酸酯化合物还可以抑制组蛋白脱乙酰酶，并且适用于选择性诱导末端分化，并阻止肿瘤细胞的细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有以肿瘤细胞增殖为特征的肿瘤的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫性，过敏性和炎性疾病，以及预防和/或治疗中枢神经系统（CNS）的疾病，例如神经退行性疾病本发明还提供包含改性丙二酸酯衍生物和这些药物组合物的安全给药方案的药物组合物，其易于遵循，并且其在体内导致治疗有效量的修饰的丙二酸酯衍生物。

7. 发明申请

US20080125100A1 MOBILE DEVICE OUTBOUND PERSONALITY PORTABILITY 审中-公开
标题翻译：移动设备外部个性便利性
公开(公告)号：US20080125100A1
公开(公告)日：2008-05-29
申请号：US11563789
申请日：2006-11-28
申请人： Paul Harrington , Leon Tong , Bill Noll
发明人： Paul Harrington , Leon Tong , Bill Noll
IPC分类号： H04M3/42
CPC分类号： H04M3/42042 , H04M2203/1091
摘要： An embodiment of the present invention includes a method to provide a calling number identifier for a non-mobile telephone associated with a mobile identification number. The method includes placing a telephone call from a non-mobile telephone, processing the telephone call placed by the non-mobile telephone, wherein processing the telephone call includes selectively associating a calling number identifier for the non-mobile telephone with a mobile identification number, and transmitting the mobile identification number as the calling number identifier to a called party.
摘要翻译：本发明的实施例包括提供与移动识别号码相关联的非移动电话的主叫号码标识符的方法。该方法包括从非移动电话放置电话呼叫，处理由非移动电话放置的电话呼叫，其中处理电话呼叫包括选择性地将非移动电话的主叫号码标识符与移动识别号码相关联，并将该移动标识号作为主叫号码标识符发送给被叫方。

8. 发明授权

US06334917B1 Propellant compositions for gas generating apparatus 失效
标题翻译：用于气体发生装置的推进剂组合物
公开(公告)号：US06334917B1
公开(公告)日：2002-01-01
申请号：US09177881
申请日：1998-10-23
申请人： Brian K. Hamilton , Paul Harrington
发明人： Brian K. Hamilton , Paul Harrington
IPC分类号： C06B4500
CPC分类号： C06B23/001 , C06B45/00 , C06D5/06
摘要： A gas generating apparatus for outputting a gas is provided. In one embodiment, the apparatus is an inflator having a propellant for supplying inflation gas(es) to an inflatable located in a vehicle. A confining member is located adjacent to the propellant. A number of spaced holes are provided in the confining member, either before or after activation of the propellant. Inflation gas is received through the spaced holes for subsequent passage to the inflatable. In that regard, the inflation gas first passes through a chamber defined in a timing member that has metering orifices. Such orifices regulate the flow of the inflation gas to the inflatable. The confining member is able to withstand significant pressures without rupturing. Each of the confining member and the timing member is preferably made of a non-metallic material. The propellant includes a fuel-rich material and an oxidizer material, preferably ammonium nitrate.
摘要翻译：提供一种用于输出气体的气体发生装置。在一个实施例中，该装置是具有用于将充气气体供应给位于车辆中的充气装置的推进剂的充气机。限制构件位于推进剂附近。在限制构件中，在推进剂活化之前或之后提供多个间隔开的孔。通过间隔开的孔容纳充气气体，以便随后通过充气。在这方面，膨胀气体首先通过限定在具有计量孔的定时构件中的室。这样的孔口将膨胀气体的流量调节到可膨胀的气体。限制构件能够承受显着的压力而不会破裂。限制构件和定时构件中的每一个优选地由非金属材料制成。推进剂包括富含燃料的材料和氧化剂材料，优选硝酸铵。

9. 发明授权

US08791147B2 Calcium receptor modulating agents 有权
标题翻译：钙受体调节剂
公开(公告)号：US08791147B2
公开(公告)日：2014-07-29
申请号：US13123468
申请日：2009-10-07
申请人： Christopher Fotsch , Paul Harrington
发明人： Christopher Fotsch , Paul Harrington
IPC分类号： A61K31/44 , C07D211/72 , C07D211/84 , C07D213/62 , C07D213/78 , C07D211/70 , C07D211/82 , C07D213/24
CPC分类号： A61K31/44 , A61K31/437 , A61K31/4412
摘要： The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula (I). Where Cy1 is pyridinonyl, pyridinyl, quinolinyl or 9-ethyl-9H-beta-carbolinyl, each of which optionally substituted and where Cy2 is phenyl naphthyl.
摘要翻译：本发明一般涉及新型的拟钙化合物和包含它们的药物组合物。本发明还涉及使用式（I）表示的化合物治疗与钙感受受体的功能有关的疾病或病症的方法。其中Cy1是吡啶基，吡啶基，喹啉基或9-乙基-9H-咔啉基，其各自任选被取代，Cy2是苯基萘基。

10. 发明申请

US20100125062A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS 有权
标题翻译：吡啶和吡嗪衍生物作为磷酸二酯酶10抑制剂
公开(公告)号：US20100125062A1
公开(公告)日：2010-05-20
申请号：US12619573
申请日：2009-11-16
申请人： Jennifer R. Allen , Kaustav Biswas , Frank Chavez, Jr. , Ning Chen , Frenel Fils Demorin , James R. Falsey , Mike Frohn , Paul Harrington , Dan Horne , Essa Hu , Matthew R. Kaller , Roxanne Kunz , Holger Monenschein , Tom Nguyen , Alex Pickrell , Andreas Reichelt , Shannon Rumfelt , Rob Rzasa , Kelvin Sham , Guomin Yao
发明人： Jennifer R. Allen , Kaustav Biswas , Frank Chavez, Jr. , Ning Chen , Frenel Fils Demorin , James R. Falsey , Mike Frohn , Paul Harrington , Dan Horne , Essa Hu , Matthew R. Kaller , Roxanne Kunz , Holger Monenschein , Tom Nguyen , Alex Pickrell , Andreas Reichelt , Shannon Rumfelt , Rob Rzasa , Kelvin Sham , Guomin Yao
IPC分类号： A61K31/4439 , C07D401/12 , C07D471/04 , C07D473/00 , C07D413/14 , C07D401/14 , A61K31/437 , A61K31/52 , A61K31/5377 , A61K31/55 , A61K31/397 , A61P25/00
CPC分类号： C07D413/14 , C07D401/12 , C07D401/14 , C07D417/12 , C07D471/04 , C07D473/00
摘要： Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
摘要翻译：吡啶和嘧啶化合物，以及含有它们的组合物，以及制备这些化合物的方法。本文还提供治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症，非胰岛素依赖型糖尿病，精神分裂症，双相情感障碍，强迫症等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式